Summit Therapeutics Inc. (NASDAQ:SMMT)
| Market Cap | 12.07B-30.4% |
| Revenue (ttm) | 0 |
| Net Income | -856.09M-55.1% |
| EPS | -1.12-47.2% |
| Shares Out | 797.75M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,658,232 |
| Open | 15.26 |
| Previous Close | 15.52 |
| Day's Range | 15.04 - 15.56 |
| 52-Week Range | 12.07 - 29.23 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 29.33(+93.85%) |
| Earnings Date | Oct 19, 2026 |
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About SMMT
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
$SMMT stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in SMMT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SMMT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SMMT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
SMMT Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Oncology clinical trial related costs | $157.73M | 68.21% |
| Stock-based compensation | $68.71M | 29.71% |
| Other income, net | $4.80M | 2.07% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New SMMT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SMMT from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in SMMT
| ETF | Est. Holding Size |
|---|---|
| XBIState Street SPDR S&P Biotech ETF | $64.94M |
| VTIVanguard Morningstar Total Stock Market ETF | $50.61M |
| VBVanguard Morningstar Small-Cap ETF | $36.47M |
| VXFVanguard Extended Market ETF | $24.60M |
| VBRVanguard Morningstar Small-Cap Value ETF | $23.17M |
| IBBiShares Biotechnology ETF | $18.05M |
Estimated from each fund’s disclosed top holdings × AUM
SMMT Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from SMMT’s recent data — informational, not investment advice